$3.35
-0.05-1.47%
Últ. Act.: Sep 11, 10:59 AM

X4 Pharmaceuticals (XFOR) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.19 | $-0.20 | $-0.35 | $-0.82 |
| Actual | $-0.13 | $-0.16 | $-0.22 | $-0.69 |
| Surprise | +31.6% | +20.0% | +37.1% | +15.8% |
| Revenue | ||||
| Estimate | $2.2M | $3.4M | $1.7M | $1.9M |
| Actual | $8.8M | $2.7M | $2.6M | $1.8M |
| Surprise | +296.7% | -19.6% | +50.0% | -7.17% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.19 | $-0.20 |
| Revenue | ||
| Consensus | $2.2M | $2.2M |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.13 | $-0.19 | 31.6 % |
| Q1 | May 6, 2026 | $-0.16 | $-0.20 | 20.0 % |
| Q4 | Mar 17, 2026 | $-0.22 | $-0.35 | 37.1 % |
| Q3 | Nov 5, 2025 | $-0.69 | $-0.82 | 15.8 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $8.81M | $2.22M | 296.7 % |
| Q1 | May 6, 2026 | $2.71M | $3.37M | -19.6 % |
| Q4 | Mar 17, 2026 | $2.57M | $1.71M | 50.0 % |
| Q3 | Nov 5, 2025 | $1.77M | $1.90M | -7.17 % |